Ulrich Abildgaard

• Abildgaard, Ulrich & Heimdal, Ketil Riddervold (2013). Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. European Journal of Obstetrics, Gynecology, and Reproductive Biology.  ISSN 0301-2115.  166(2), s 117- 123 . doi: 10.1016/j.ejogrb.2012.09.026
• Andresen, Marianne Seierstad; Sandven, Irene; Brunborg, Cathrine; Johansen, Anne Mette; Strekerud, Finn; Abdelnoor, Michael; Smith, Pål & Abildgaard, Ulrich (2011). Mortality and recurrence after treatment of VTE: Long term follow-up of patients with good life-expectancy. Thrombosis Research.  ISSN 0049-3848.  127(6), s 540- 546 . doi: 10.1016/j.thromres.2011.02.017
• Abildgaard, Ulrich; Sandset, Per Morten; Hammerstrøm, Jens; Gjestvang, Finn Tore & Tveit, Arnljot (2009). Management of pregnant women with mechanical heart valve prosthesis: Thromboprophylaxis with Low molecular weight heparin. Thrombosis Research.  ISSN 0049-3848.  124(3), s 262- 267 . doi: 10.1016/j.thromres.2008.12.005
• Andresen, Marianne Seierstad; Eilertsen, Anette Løken; Abildgaard, Ulrich & Sandset, Per Morten (2007). Hormone therapy and raloxifene reduce the coagulation inhibitor potential. Blood Coagulation and Fibrinolysis.  ISSN 0957-5235.  18, s 455- 460 Show summary

  Background The Coagulation Inhibitor Potential (CIP) assay is a global assay that may detect major thrombophilia at a sensitivity of 100% and a specificity of 70-80%. Subnormal CIP may be associated with increased risk of venous thromboembolism (VTE). Aims Compare the effect on CIP in plasma samples from postmenopausal women treated with four different therapeutic regimens. Methods Fibrin aggregation in plasma was monitored after activation of coagulation with tissue factor, and the effect of potentiated inhibition of coagulation was measured. The assay was performed on plasma samples from 202 healthy women who were randomly assigned to receive treatment for twelve weeks with conventional-dose hormone therapy (HT), low-dose HT, raloxifene or tibolone. Major thrombophilias were excluded. Twelve women were heterozygous carriers of the factor V Leiden mutation. Results Compared to baseline the median level in CIP was reduced by 64% in the conventional-dose HT group, by 38% in the low-dose HT group, 31% in the raloxifene group, whereas for those treated with tibolone median CIP increased by 9%. The median changes in CIP were significant for both the HT groups (P  0.0001) and for those allocated to raloxifene (P = 0.003), but not for the tibolone group (P = 0.653). Women with heterozygous factor V Leiden mutation had significantly reduced median CIP level (P  0.0001) at baseline. Conclusions: HT and raloxifene, associated with VTE, reduce CIP. Tibolone does not reduce CIP.

• Brosstad, Frank; Abildgaard, Ulrich; Breivik, Harald & Sellevold, Olav F Münter (2007). Marevan og blodplatehemmere ved kirurgi. Tidsskrift for Den norske legeforening.  ISSN 0029-2001. Show summary

  Innlegget er trykket som supplement til Tidsskriftet og er retningslinjer for kombinasjonen antikoagulerende behandling og kirurgi. Det er en rekke medforfattere, spesielt hematologer, kirurger og anestesiologer hvorav OFMS er en.

• Jacobsen, EM; Trettenes, EJ; Wisløff, Finn Georg B & Abildgaard, Ulrich (2006). Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene. Thrombosis Journal.  ISSN 1477-9560.  4, s 3- 8
• Andresen, Marianne S; Abildgaard, Ulrich; Liestøl, Sigurd; Sandset, Per Morten; Mowinckel, M.C.; Ødegaard, Ole Rasmus; Larsen, ML. & Diep, Lien (2004). The ability of three global plasma assays to recognize thrombophilia. Thrombosis Research.  ISSN 0049-3848.  113(6), s 411- 7 Show summary

  Three global assays, the Calibrated Automated Thrombogram (CAT), the ProC Global (PCG), and the Coagulation Inhibitor Potential (CIP) were performed in frozen plasma samples from 24 normal controls and 24 patients with inherited thrombophilia. Six patients had inherited antithrombin (AT) deficiency; 18 patients had abnormalities in the protein C/S anticoagulant system (protein C deficiency (n=3), protein S deficiency (n=10), homozygous FV Leiden mutation (n=5)). Nine of these twenty four patients carried additionally the heterozygous FV Leiden mutation. All three assays separated the thrombophilia group and the control group (P=0.083 for CAT, P<0.0001 for the other two assays) but there was considerable overlap, particularly in the CAT assay. The CAT assay separated all plasma samples with AT deficiency but was less sensitive to abnormalities in the protein C/S system. In contrast, ProC Global was more sensitive to abnormalities in the protein C system than to AT deficiency. The CIP assay was approximately equally sensitive to defects in both systems. Receiver operator characteristic (ROC) curves confirmed that the ProC Global and the CIP assays performed better than the CAT assay (P=0.0179 and P=0.0003, respectively). With the CIP assay ROC analysis showed that with a sensitivity of 100% the specificity was 87.5%. With the PCG assay, optimal threshold resulted in both a sensitivity and a specificity of 79.2%. Although our material is relatively small, the data suggest that at a cut-off value with a specificity of >80%, the CIP assay should be evaluated as a screening test for severe thrombophilia.

• Sandset, Per Morten & Abildgaard, Ulrich (2004). Tissue factor pathway inhibitor revisited. Journal of Thrombosis and Haemostasis.  ISSN 1538-7933.  2(12), s 2242- 2243
• Iversen, Nina; Lindahl, Anne Karin & Abildgaard, Ulrich (2002). Elevated plasma Levels of the factor Xa-TFPI complex in cancer patients. Thrombosis Research.  ISSN 0049-3848.  105(1), s 33- 36 . doi: 10.1016/S0049-3848(01)00404-2
• Boffa, Marie-Claire; Lapeyrere, C; Berard, M; Lindahl, Anne Karin; Flageul, B; Chemaly, P; Abildgaard, Ulrich & Dubertret, L (1994). Plasma thrombomodulin Level in malignancy varies according to the tumor type. La Nouvelle revue francaise.  ISSN 0029-4802.
• Abildgaard, Ulrich; Sandset, Per Morten & Lindahl, Anne Karin (1993). Tissue Factor Pathway Inhibitor, In L Poller (ed.),  Recent Advances in Blood Coagulation 6.  Churchill Livingstone.  ISBN 978-0443047558.  I.
• Lindahl, Anne Karin; Boffa, Marie-Claire & Abildgaard, Ulrich (1993). Increased plasma thrombomodulin in cancer patients. Thrombosis and Haemostasis.  ISSN 0340-6245.
• Lindahl, Anne Karin; Boffa, Marie-Claire & Abildgaard, Ulrich (1993). Tissue factor pathway inhibitor. Thrombosis and Haemostasis.  ISSN 0340-6245.
• Kristensen, HI; Østergaard, PB; Nordfang, O; Abildgaard, Ulrich & Lindahl, Anne Karin (1992). Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin. Thrombosis and Haemostasis.  ISSN 0340-6245.
• Lindahl, Anne Karin; Sandset, Per Morten & Abildgaard, Ulrich (1992). The present status of tissue factor pathway inhibitor. Blood Coagulation and Fibrinolysis.  ISSN 0957-5235.
• Abildgaard, Ulrich; Lindahl, Anne Karin & Sandset, Per Morten (1991). Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. Thrombosis and Haemostasis.  ISSN 0340-6245.
• Lindahl, Anne Karin; Abildgaard, Ulrich; Larsen, ML; Aamodt, LM; Nordfang, O & Beck, TC (1991). Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thrombosis Research.  ISSN 0049-3848.
• Lindahl, Anne Karin; Abildgaard, Ulrich; Larsen, ML; Staalesen, R; Hammer, AK; Sandset, PM; Nordfang, O & Beck, TC (1991). Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thrombosis Research.  ISSN 0049-3848.
• Lindahl, Anne Karin; Abildgaard, Ulrich & Staalesen, R (1991). The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thrombosis Research.  ISSN 0049-3848.
• Lindahl, Anne Karin; Jacobsen, PB; Sandset, Per Morten & Abildgaard, Ulrich (1991). Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagulation and Fibrinolysis.  ISSN 0957-5235.
• Norrheim, L; Abildgaard, Ulrich; Larsen, ML & Lindahl, Anne Karin (1991). Involvement of the extrinsic pathway in the activities of low molecular weight heparins. Thrombosis Research.  ISSN 0049-3848.
• Sandset, Per Morten; Larsen, ML; Abildgaard, Ulrich; Lindahl, Anne Karin & Ødegaard, OR (1991). Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): Levels in the normal population and relation to cholesterol. Blood Coagulation and Fibrinolysis.  ISSN 0957-5235.
• Lindahl, Anne Karin; Abildgaard, Ulrich & Stokke, G (1990). Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thrombosis Research.  ISSN 0049-3848.
• Lindahl, Anne Karin; Sandset, Per Morten & Abildgaard, Ulrich (1990). Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. Thrombosis and Haemostasis.  ISSN 0340-6245.
• Lindahl, Anne Karin; Sandset, Per Morten; Abildgaard, Ulrich; Andersson, TR & Harbitz, Thorstein Backe (1989). High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chiropterologica.  ISSN 1508-1109.

View all works in Cristin

• Toth, Orsolya; Conard, Jacqueline; Losonczy, Hajna; Reger, Barbara; Andresen, Marianne Seierstad; Horellou, Marie-Helene; Mozes, Reka & Abildgaard, Ulrich (2012). High sensitivity of the global CIP assay for hereditary thrombophilia. Thrombosis Research.  ISSN 0049-3848.  130, s S133- S133 . doi: 10.1016/j.thromres.2012.08.085

View all works in Cristin